Medical interventions for infectious disease outbreaks fall into three broad categories: drugs that attack the pathogen directly, immune-based therapies that help the body fight the infection, and supportive treatments that keep patients alive while their immune system catches up. The specific tools range from antiviral pills and monoclonal antibodies to reactive vaccination campaigns and aggressive fluid replacement. Which interventions get deployed depends on whether the pathogen is viral or bacterial, how far the outbreak has progressed, and what treatments already exist on the shelf or can be adapted quickly from other diseases.
Antivirals and the Speed Problem
The frontline pharmacological weapons against viral outbreaks are small-molecule antivirals. These drugs interfere with specific steps in a virus’s life cycle, blocking it from entering cells, copying its genetic material, or assembling new viral particles. Some act as polymerase inhibitors that jam the virus’s replication machinery, while others function as protease inhibitors that prevent newly made viral proteins from being cut into functional pieces.1PubMed Central. A review: Mechanism of action of antiviral drugs The challenge is that developing a brand-new antiviral for a novel pathogen takes years, and outbreaks do not wait.
This is where drug repurposing becomes critical. Rather than starting from scratch, researchers screen existing approved medications to see if any happen to work against the new threat. The strategy gained enormous momentum during COVID-19 and has become a standard part of outbreak response planning. Remdesivir, originally developed for Ebola, became one of the first authorized treatments for SARS-CoV-2. Favipiravir, designed for influenza, was trialed against multiple emerging viruses.2PubMed Central. Drug Repurposing for Viral Infectious Diseases: How Far Are We? The approach is not limited to viruses, either. Sanfetrinem, a carbapenem antibiotic shelved in the 1990s, has been repurposed as a candidate for treating tuberculosis, including multi-drug-resistant strains, and has entered a Phase 2a clinical trial in South Africa.3PubMed Central. Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis
Repurposing has real limitations, though. A drug that shows antiviral activity in a lab dish often fails to achieve useful concentrations in human tissue. And the enthusiasm around certain repurposed drugs during COVID-19, particularly hydroxychloroquine, ran far ahead of the evidence, with consequences discussed further below.
Monoclonal Antibodies
Monoclonal antibodies are lab-made proteins designed to bind a specific target on a pathogen, neutralizing it or flagging it for destruction by the immune system. During outbreaks, they serve as both a treatment for the already infected and a form of short-term protection for people who have been exposed. Among the three main categories of medical countermeasures against emerging viral threats, monoclonal antibodies, antivirals, and vaccines, antibodies occupy a unique middle ground: they act faster than vaccines but are far more expensive and harder to scale.4PubMed Central. Lessons for medical countermeasure development from unforeseen outbreaks
Ebola provides the clearest success story. Monoclonal antibody cocktails became the most effective treatment for reversing lethal Ebola infections in animal models, and newer combinations could cure animals even after symptoms and detectable virus had appeared.5PubMed Central. Antibody therapy for Ebola: is the tide turning around? Researchers have since developed broadly protective antibody therapies designed to work across multiple Ebola virus species. One of these, MBP134AF, was deployed during a Sudan ebolavirus outbreak in Uganda, marking a real-world test of next-generation antibody therapy in an active epidemic.6PubMed. A review of broadly protective monoclonal antibodies to treat Ebola virus disease The potential for monoclonal antibodies to serve as targeted post-exposure prophylaxis for high-risk contacts is also gaining ground, with the rationale that giving antibodies to people who have been directly exposed to a patient could halt transmission chains before they grow.7PubMed. Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis
Reactive Vaccination and Ring Vaccination
Vaccines are the backbone of long-term outbreak prevention, but they also play a reactive role once an outbreak is already underway. Ring vaccination, where you vaccinate the contacts and contacts-of-contacts of each confirmed case, is one of the most studied reactive strategies. It was famously used to eradicate smallpox and was tested against Ebola during the West Africa epidemic and subsequent flare-ups.
The results are instructive about what ring vaccination can and cannot do. Modeling work suggests that adding ring vaccination at the very start of the massive West Africa Ebola epidemic might not have contained it on its own, because transmission was too intense and control infrastructure too weak. But in later stages, or in smaller outbreaks with more manageable transmission, ring vaccination could help eliminate the disease.8PubMed Central. Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease The type of vaccine matters enormously, too. Modeling of the Ebola response found that a vaccine capable of conferring post-exposure protection could avert roughly five to seven percent of additional cases in Liberia and Sierra Leone when combined with non-pharmaceutical measures, compared with less than one percent for a purely prophylactic vaccine.9PLOS Neglected Tropical Diseases. Harnessing Case Isolation and Ring Vaccination to Control Ebola
In 2016, a flare-up in Guinea provided the first real-world deployment of the rVSV-ZEBOV Ebola vaccine using ring vaccination outside of a clinical trial. The operational report confirmed that ring vaccination could be rapidly and safely implemented at scale even in rural, resource-limited settings.10PubMed Central. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016
Post-Exposure Prophylaxis
Post-exposure prophylaxis, or PEP, is the practice of giving a vaccine or immune product to someone after they have been exposed to a pathogen but before they develop symptoms. It works because many infections have an incubation period long enough for a medical intervention to prime the immune system or neutralize the pathogen before it gains a foothold.
Measles is a textbook PEP case. A systematic review found that both measles-containing vaccine PEP and immune globulin PEP are highly effective. Effectiveness estimates for immune globulin ranged from about 76 to 100 percent, and vaccine PEP ranged from about 83 to 100 percent across studies.11PubMed. Post-exposure prophylaxis for the prevention of measles: A systematic review During a 2013 outbreak in New York City, no contact who received immune globulin PEP developed measles, and vaccine PEP showed effectiveness of about 83 percent.12PubMed. Effectiveness of Measles Vaccination and Immune Globulin Post-Exposure Prophylaxis in an Outbreak Setting-New York City, 2013 PEP is not unique to measles; the same principle applies to rabies, hepatitis B, and, increasingly, Ebola via monoclonal antibody administration to exposed contacts.
Convalescent Plasma and Passive Immunization
Before monoclonal antibodies became widely available, convalescent plasma, blood products taken from patients who had recovered from an infection, was often the fastest way to deliver ready-made antibodies to acutely ill patients. The approach has been used in outbreaks of influenza, SARS, Ebola, and COVID-19. Its advantage is speed: once you have recovered patients willing to donate, you can begin treatment without waiting for a new drug to be manufactured.13PubMed Central. A Roadmap for the Application of Convalescent Plasma and Hyperimmune Globulins in Emerging Viral Outbreaks
COVID-19 provided the largest-ever test of this strategy. The evidence that emerged was mixed overall but suggested that high-titer convalescent plasma could add benefit when given early in infection and to patients with weaker immune responses.14Process Biochemistry. Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update – Section: Dosing and clinical aspects of the therapy For later-stage disease in patients with robust immune systems, it added little. This pattern, where timing and patient selection determine whether passive immunization works, has held across different outbreaks.
Supportive Care as a Lifesaver
It is easy to overlook supportive care in a discussion of high-tech interventions, but for many outbreak pathogens, especially those without specific antiviral treatments, keeping the patient alive long enough for their immune system to clear the infection is the intervention. During the Ebola epidemic, aggressive fluid replacement and electrolyte correction were among the most impactful measures available. Evidence-based guidelines strongly recommend parenteral fluid administration for patients unable to drink or whose losses exceed oral intake, as it likely reduces mortality.15PubMed Central. Evidence-based guidelines for supportive care of patients with Ebola virus disease – Section: Parenteral administration of fluids
A case report of two Ebola patients treated in the United States illustrated how intensive supportive care can work. Both patients had severe fluid depletion and electrolyte imbalances. The medical team administered three to five liters of intravenous fluids per day during the early course of care, corrected electrolytes, and both patients survived, with a corresponding decline in detectable virus in their blood as they improved.16PubMed. Clinical care of two patients with Ebola virus disease in the United States The disparity between survival rates in well-resourced settings versus field hospitals during Ebola underscored just how much aggressive supportive care can matter, even when no targeted drug is available.
Antibiotics and Mass Chemoprophylaxis
Not all outbreaks are viral. For bacterial diseases, antibiotics are both the treatment and, in some cases, the outbreak-control strategy. Mass chemoprophylaxis involves giving antibiotics to an entire community or defined population to eliminate carriage of the organism and break transmission chains. Meningococcal disease outbreaks are the most common setting for this approach. A review of outbreak reports found that in most cases, no additional cases of meningococcal disease occurred after mass chemoprophylaxis, or cases occurred only in people who did not receive the antibiotics.17PubMed Central. Mass chemoprophylaxis for control of outbreaks of meningococcal disease
The approach does not always work, however. In one well-documented case, mass antibiotic prophylaxis in an Israeli village failed to eradicate carriage of the outbreak strain and did not reduce the incidence or fatality rate.18PubMed. Failure of mass antibiotic prophylaxis to control a prolonged outbreak of meningococcal disease in an Israeli village This highlights a recurring tension in outbreak response: mass antibiotic use can provide temporary protection but risks driving resistance, and when it fails, the outbreak may be harder to control afterward.
Immunomodulatory Therapies
Sometimes the pathogen itself is not the only thing killing the patient. The body’s own immune response can become dangerously overactive, producing a flood of inflammatory signals that damages the lungs and other organs. COVID-19 made this dynamic visible to the general public under the term “cytokine storm.” Corticosteroids like dexamethasone became a standard treatment for severe COVID-19 precisely because they suppress this runaway inflammation. Dexamethasone and methylprednisolone showed particular efficacy in patients who needed mechanical ventilation.19PubMed Central. A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms
The tricky part is timing. Corticosteroids suppress the immune response broadly, which means giving them too early, before the immune system has had a chance to fight the virus, can actually make things worse by letting the pathogen replicate unchecked. The lesson from COVID-19 is that immunomodulatory therapies need to be matched to the stage of disease, helpful during the inflammatory phase, potentially harmful during the early viral-replication phase.
Drug Resistance During Outbreaks
Deploying antivirals or antibiotics at scale during an outbreak creates selection pressure for drug-resistant strains, and the timing of that deployment matters more than you might expect. Modeling work has shown that the direct benefits of antimicrobials are actually maximized by delaying their use until the epidemic is well underway rather than starting from day one. The logic is counterintuitive: if drug-sensitive strains get a head start and make up the bulk of early cases, resistant mutants that arise later will remain a small fraction of the total. Deploying drugs immediately risks creating resistant clones early, when the epidemic population is still growing, letting those clones expand into a large fraction of all cases.20PubMed Central. Timing of antimicrobial use influences the evolution of antimicrobial resistance during disease epidemics
Pandemic influenza modeling reinforces this concern. Moderate to high treatment levels can deplete antiviral stockpiles more rapidly and promote widespread drug resistance, potentially leaving the population more vulnerable in later waves.21PubMed Central. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use Combination therapy, where two or more drugs with different mechanisms are given together, is one strategy for reducing resistance risk while potentially improving efficacy. Drug combinations can produce additive or synergistic effects against viruses like influenza, Ebola, Zika, and SARS-CoV-2.22PubMed Central. Drug combination therapy for emerging viral diseases
How Treatments Get Authorized Fast Enough
Traditional drug approval takes years. Outbreaks move in weeks. Bridging that gap requires special regulatory pathways. In the United States, the Emergency Use Authorization process, which originated in 2004 in response to bioterrorism concerns, allows the FDA to authorize unapproved medical products when a public health emergency has been declared.23PubMed Central. The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic COVID-19 saw this pathway used at unprecedented scale for diagnostics, therapeutics, and vaccines. Expanded Access programs, which allow compassionate use of unapproved drugs outside of clinical trials, also saw a surge during the pandemic.24PubMed Central. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic
Adaptive platform trials represent another acceleration strategy. Traditional trials test one drug at a time. Platform trials like RECOVERY and REMAP-CAP test multiple treatments simultaneously against a shared control arm, drop treatments that are failing at interim analyses, and add new candidates as they become available.25PubMed Central. Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings RECOVERY alone generated definitive evidence on dexamethasone, convalescent plasma, and several other COVID-19 treatments in a fraction of the time that separate traditional trials would have required. The design has since been proposed as a standing model for future pandemics, including for assessing therapeutics in hospitalized influenza patients.26The Journal of Infectious Diseases. Platform Trials to Assess Therapeutics in Patients Hospitalized With Influenza
The Risks of Off-Label and Unproven Treatments
The urgency of an outbreak creates enormous pressure to try anything that might work, and that pressure can backfire. Off-label prescribing, using an approved drug for an unapproved purpose, is legal in most countries and sometimes medically justified as a last resort. But during COVID-19, the widespread off-label use of hydroxychloroquine became a cautionary tale. The unregulated enthusiasm sent a misleading signal to the public that the drug had preventive or treatment effects before adequate evidence existed. It also undermined the government’s ability to develop high-quality safety and efficacy data, pulling patients and resources away from potentially better-justified treatments and clinical trials that could have generated clear answers faster.27Journal of Law and the Biosciences. The enhanced danger of physicians’ off-label prescribing during a public health emergency – Section: Do altered standards of care in a pandemic justify unrestricted OLU?
The core problem is that a drug used as a “Hail Mary” in an individual desperate case is very different from that same drug being prescribed to thousands of people outside of any trial framework. The former is a defensible medical judgment. The latter creates the illusion of established treatment while preventing the rigorous evaluation that could settle the question.
Diagnostics and Their Role in Guiding Treatment
Medical interventions work better when you know what you are treating. Point-of-care diagnostic tools, rapid tests that can be performed at the bedside or in a field clinic rather than sent to a distant laboratory, have become an increasingly important part of outbreak response. They enable faster treatment decisions, allow clinicians to distinguish the outbreak pathogen from other infections with similar symptoms, and support surveillance efforts that track how and where the outbreak is moving.28PubMed Central. Impact of Point-of-Care Testing on Diagnosis, Treatment, and Surveillance of Vaccine-Preventable Viral Infections During COVID-19, the availability of rapid antigen tests shaped whether patients received antivirals like nirmatrelvir/ritonavir within the narrow treatment window when those drugs are effective. Without rapid diagnostics, even the best treatments lose impact because they arrive too late.
Broad-Spectrum Antivirals and Preparing for the Unknown
A major vulnerability in outbreak response is that most antivirals are virus-specific. When a novel pathogen emerges, you may have nothing on the shelf that works against it. Broad-spectrum antivirals, drugs active against multiple viral families, are being developed as a hedge against this problem. Several repurposed drugs including favipiravir, remdesivir, niclosamide, and nitazoxanide have shown activity across viral families including coronaviruses, flaviviruses, orthomyxoviruses, and poxviruses.29PubMed Central. Strategic Preparedness of Broad-Spectrum Antivirals for Rapid Response Towards Next Pandemics
High-throughput screening platforms are also being built for rapid deployment. One such platform screened roughly 900,000 compounds against multiple SARS-CoV-2 variants, the original SARS virus, and a common human coronavirus to identify candidates with broad-spectrum activity and limited off-target effects.30PubMed. A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects The goal is to have these screening tools ready to go before the next pandemic so that candidate drugs can be identified within weeks of a new pathogen being sequenced, rather than months.
Getting Treatments to Where They Are Needed
Having an effective intervention is only half the battle. Getting it distributed equitably, especially to low- and middle-income countries where many outbreaks begin, remains one of the hardest challenges in outbreak response. COVID-19 exposed stark inequities in vaccine and therapeutic access. mRNA vaccines, for instance, require ultra-cold-chain storage, which is achievable even in resource-limited settings (as demonstrated during the Ebola response in the Democratic Republic of the Congo, where ultra-cold storage and backup generators were deployed), but demands significant investment in infrastructure, money, and health staff. Without resolving these logistics, mRNA vaccines may have a limited role in the world’s lower-income countries, and vaccine platforms without complex cold-chain requirements should be encouraged to bridge the gap.31The Lancet. Status of COVID-19 vaccines, therapeutics, health systems, global policy, and security
Pregnant women represent another access gap. Response plans for outbreaks often include medications and vaccines for which the effects on pregnancy and fetal development are unknown. Healthcare providers face the difficult task of weighing the risks of an untested intervention against the risks of a potentially fatal infection, and formal guidance is often lacking.32PubMed Central. Prophylaxis and treatment of pregnant women for emerging infections and bioterrorism emergencies Experiences with SARS, monkeypox, anthrax response planning, and pandemic influenza have repeatedly highlighted this gap without fully closing it.
Vector Control as a Medical-Adjacent Intervention
For diseases transmitted by mosquitoes, ticks, or other arthropods, medical treatment of infected patients is only part of the picture. Vector control, reducing or eliminating the insect populations that spread the pathogen, is an intervention that sits at the border between medicine and public health. One emerging approach is mass administration of endectocides, drugs like ivermectin that kill insects when they bite a treated human or animal host. Studies of this approach for malaria control have used doses ranging from 150 to 400 micrograms per kilogram, targeting Anopheles mosquitoes through treated humans and livestock.33PubMed Central. Endectocides as a complementary intervention in the malaria control program: a systematic review Results so far have been mixed, with further large-scale trials in Mozambique and Kenya still pending.34The Lancet Planetary Health. Prospecting the global phase-out of dichlorodiphenyltrichloroethane for disease vector control The concept is appealing because it piggybacks on existing mass drug administration infrastructure, but whether it delivers meaningful population-level reductions in disease transmission is still an open question.